plasminogen
activ
sputum
nasal
lavag
fluid
increas
asthmat
patient
common
cold
editor
possibl
recurr
asthma
exacerb
associ
common
cold
promot
airway
remodel
suggest
find
acceler
lung
function
declin
time
patient
asthma
frequent
exacerb
presum
caus
loss
lung
function
asthma
airway
remodel
one
inflammatori
mediat
thought
promot
airway
remodel
plasminogen
activ
inhibit
fibrinolyt
system
matrix
metalloproteinas
system
previous
report
highli
express
patient
fatal
asthma
elev
plasma
level
associ
diminish
forc
vital
capac
report
common
cold
associ
increas
product
airway
asthmat
subject
fiftytwo
asthmat
subject
subject
allerg
rhiniti
healthi
control
evalu
within
day
cold
onset
visit
day
cold
symptom
visit
week
longer
thereaft
assess
baselin
statu
visit
visit
induc
sputum
nasal
lavag
fluid
nlf
sampl
collect
spirometri
perform
describ
previous
virochip
use
detect
virus
visit
allergi
skin
test
perform
visit
assess
atopi
studi
approv
intern
review
board
univers
california
san
francisco
northwestern
univers
concentr
sputum
nlf
determin
use
elisa
assaypro
st
charl
mo
statist
analys
perform
prism
softwar
version
graphpad
san
diego
calif
first
group
compar
use
kruskalw
test
tabl
higher
proport
allerg
rhiniti
asthmat
subject
atop
compar
healthi
control
asthmat
subject
lowest
fev
signific
differ
age
sex
among
group
proport
respiratori
viru
detect
similar
asthmat
healthi
subject
vs
among
detect
virus
rhinoviru
preval
subject
group
baselin
sputum
level
significantli
higher
asthmat
subject
nonasthmat
control
median
interquartil
rang
vs
ngml
p
fig
asthmat
patient
sputum
level
increas
significantli
day
compar
baselin
level
p
fig
b
wherea
chang
significantli
nonasthmat
subject
see
fig
articl
onlin
repositori
wwwjacionlineorg
sputum
level
asthmat
patient
exacerb
fev
drop
n
higher
without
exacerb
n
although
statist
signific
vs
ngml
day
p
vs
ngml
day
p
signific
differ
baselin
nlf
level
asthmat
nonasthmat
subject
vs
ngml
p
level
nlf
sampl
asthmat
patient
significantli
higher
day
day
baselin
p
p
respect
fig
c
interestingli
asthmat
subject
earli
elev
level
day
nlf
sampl
observ
nlf
sampl
nonasthmat
subject
see
fig
articl
onlin
repositori
wwwjacionlineorg
investig
whether
rhinoviru
preval
common
cold
viru
induc
airway
epitheli
cell
asthmat
subject
produc
obtain
cultur
primari
nasal
epitheli
cell
submerg
medium
asthmat
subject
treat
either
human
rhinoviru
hrv
serotyp
multipl
infect
vehicl
control
hour
level
supernat
infect
cultur
asthmat
patient
increas
significantli
compar
noninfect
cultur
p
fig
result
show
baselin
sputum
level
significantli
higher
asthmat
patient
versu
nonasthmat
control
addit
common
cold
increas
level
upper
lower
airway
asthmat
subject
control
subject
lastli
vitro
hrv
induc
epitheli
product
data
increas
sputum
level
baselin
asthma
similar
previou
report
previou
studi
suggest
may
relat
airway
obstruct
extracellular
matrix
deposit
airway
wall
also
intralumin
fibrin
deposit
may
explain
least
part
mechan
frequent
exacerb
may
caus
progress
airway
obstruct
subset
patient
reduct
fev
associ
histori
frequent
exacerb
asthmat
patient
similar
studi
asthmat
subject
cold
show
high
level
fibrinogen
induc
sputum
day
hypothes
highli
elev
fibrinogen
level
airway
asthmat
subject
potenti
convers
fibrin
degrad
elev
local
level
occurr
may
lead
airway
obstruct
although
could
find
neg
correl
sputum
level
lung
function
due
small
sampl
size
found
patient
high
sputum
level
day
day
fig
b
among
patient
signific
asthma
exacerb
fev
drop
would
interest
conduct
studi
observ
recent
studi
show
sputum
level
significantli
higher
patient
longer
durat
shorter
durat
asthma
result
rais
hypothesi
repeat
respiratori
viral
infect
may
lead
repeat
transient
increas
airway
level
suscept
asthmat
patient
sever
year
could
lead
acceler
remodel
progress
airway
obstruct
summari
studi
demonstr
lower
airway
level
higher
asthmat
subject
healthi
subject
common
cold
increas
upper
lower
airway
level
asthmat
subject
result
may
explain
associ
recurr
exacerb
persist
lower
airway
obstruct
studi
need
understand
whether
elev
level
lead
accumul
fibrin
extracellular
matrix
airway
asthmat
patient
editor
adenosin
deaminas
ada
ubiquit
enzym
import
metabol
adenosin
deoxyadenosin
inherit
defect
function
ada
lead
sever
immun
abnorm
increas
suscept
lethal
infect
current
treatment
ada
defici
includ
allogen
hematopoiet
stem
cell
transplant
autolog
gene
therapi
enzym
replac
therapi
bovin
ada
conjug
polyethylen
glycol
pegada
recent
identifi
accumul
surfactantlik
substanc
suggest
pulmonari
alveolar
proteinosi
pap
adadefici
patient
pap
rare
lung
disord
character
impair
pulmonari
surfact
homeostasi
result
progress
respiratori
failur
establish
understand
role
ada
defici
develop
pap
studi
adadefici
adako
mice
see
method
section
articl
onlin
repositori
wwwjacionlineorg
addit
inform
display
mani
metabol
immun
system
abnorm
observ
adadefici
patient
previou
report
found
increas
bronchial
airway
mucu
inflammatori
cell
accumul
structur
abnorm
lung
adako
mice
although
pap
describ
adako
mice
die
age
day
previous
fig
sputum
level
nonasthmat
subject
healthi
control
green
upward
triangl
allerg
rhiniti
red
downward
triangl
day
day
common
cold
onset
compar
baselin
visit
wilcoxon
pair
test
red
line
indic
median
valu
p
fig
nasal
lavag
fluid
level
nonasthmat
subject
healthi
control
green
upward
triangl
allerg
rhiniti
red
downward
triangl
day
day
common
cold
onset
compar
baselin
visit
wilcoxon
pair
test
p
